Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04462328
Title Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

central nervous system lymphoma

Therapies

Acalabrutinib + Durvalumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.